BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 15982322)

  • 1. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
    Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
    Lam MM; Corless CL; Goldblum JR; Heinrich MC; Downs-Kelly E; Rubin BP
    Int J Gynecol Pathol; 2006 Jul; 25(3):288-92. PubMed ID: 16810068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
    Sakamoto K; Sakurai S; Kanda T; Sakuma Y; Hishima T; Hironaka M; Bamba T; Keira Y; Takano Y; Niki T; Hasegawa T; Hirota S
    Cancer Sci; 2010 May; 101(5):1270-8. PubMed ID: 20180814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
    J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
    Herawi M; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2006 Nov; 30(11):1389-95. PubMed ID: 17063078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
    Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A
    Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric GISTs. Personal experience.
    Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
    Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).
    Miettinen M; Sobin LH; Sarlomo-Rikala M
    Mod Pathol; 2000 Oct; 13(10):1134-42. PubMed ID: 11048809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
    Sciot R; Debiec-Rychter M; Daugaard S; Fisher C; Collin F; van Glabbeke M; Verweij J; Blay JY; Hogendoorn PC; ; ;
    Eur J Cancer; 2008 Sep; 44(13):1855-60. PubMed ID: 18653326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses.
    Kikuchi H; Yamashita K; Kawabata T; Yamamoto M; Hiramatsu Y; Kondo K; Baba M; Ohta M; Kamiya K; Tanaka T; Suzuki S; Kitagawa K; Kitagawa M; Sugimura H; Konno H
    Cancer Sci; 2006 Feb; 97(2):127-32. PubMed ID: 16441423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis.
    Min KW
    Ultrastruct Pathol; 2010 May; 34(3):174-88. PubMed ID: 20455665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.